143 / 1084
Current study- ESOPEC (Germany)
R
A
N
Primary endpoint: survival
N=438
Neoadjuvant
Radio-CTX
–
CROSS Regimen
RESECTION
© Universitätsmedizin Leipzig: University Cancer Center Leipzig (UCCL), Prof. Dr. F. Lordick
Hoeppner J et al.
BMC Cancer.
2016 Jul 19;16:503.
D
O
M
3-year-OS-rate
55% CROSS vs. 68% FLOT)
T1N1M0
or
T2–4aN0–1M0
Perioperative
CTX
:
FLOT* 4 x pre and post
RESECTION
*FLOT = 5-Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel